Showing results (1-10 of 151) with videos related to

Sort By:
Pageof 16
The Journal of Antimicrobial Chemotherapy|December 1, 2020
Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?Sabira Tahseen, Armand Van Deun, Bouke C de Jong, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 17, 2021
Pretomanid for tuberculosis: a systematic reviewTinne Gils, Lutgarde Lynen, Bouke C de Jong, et al.
Jac-Antimicrobial Resistance|March 31, 2022
Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic reviewJahan Saeed Mallick, Parvati Nair, Elizabeth Tabitha Abbew, et al.
Journal of Clinical Medicine|December 29, 2019
Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of EvidenceArnaud Trébucq, Tom Decroo, Armand Van Deun, et al.
Open Forum Infectious Diseases|February 22, 2021
Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two CasesJean Claude S Ngabonziza, Tom Decroo, Rodrigue Maniliho, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|August 24, 2020
Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimenPauline Lempens, Tom Decroo, Kya J M Aung, et al.
Jac-Antimicrobial Resistance|April 13, 2022
Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settingsArmand Van Deun, Valentin Bola, Rossin Lebeke, et al.
Microbial Genomics|September 26, 2023
Borderline rpoB mutations transmit at the same rate as common rpoB mutations in a tuberculosis cohort in BangladeshPauline Lempens, Armand Van Deun, Kya J M Aung, et al.
Plos One|September 1, 2020
Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomesTom Decroo, Aung Kya Jai Maug, Mohamed Anwar Hossain, et al.
International Journal of Antimicrobial Agents|October 19, 2019
World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forwardArmand Van Deun, Tom Decroo, Sabira Tahseen, et al.
Pageof 16